# US 2021/0275486 A1 · Renal function maintenance and protection agent, and method for evaluating effect thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275486 A1
- Document ID: US20210275486A1
- Status: Published application
- Kind: A1
- Application number: 17/254,256
- Filed: 2019-07-19
- Published: 2021-09-09
- Earliest claimed: 2018-06-21
- Assignees: Maruha Nichiro Corporation
- Applicants: Maruha Nichiro Corporation
- Inventors: Masataka KAWARASAKI; Yosuke CHIBA; Akira KAMATA; Tomoaki HASHIMOTO; Yoichiro SHIRAHAMA
- Web page: https://patentgrep.com/patent/US20210275486A1

## CPC

- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- G01N 33/6893: {related to diseases not provided for elsewhere}
- A23K 20/158: Fatty acids; Fats; Products containing oils or fats
- A23L 33/115: Fatty acids or derivatives thereof; Fats or oils
- A23L 33/12: Fatty acids or derivatives thereof
- A23L 33/40: {Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 31/232: having three or more double bonds, e.g. etretinate
- A61P 13/12: of the kidneys
- G01N 33/6812: {Assays for specific amino acids}
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- G01N 2800/347: Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A23K: FODDER
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

Provided is a renal function maintenance and protection agent comprising as an active ingredient of a triglyceride of docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) or a mixture of a triglyceride of docosahexaenoic acid (DHA) and a triglyceride of eicosapentaenoic acid (EPA), which can be used as a pharmaceutical or food composition. A triglyceride of docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) or a mixture of a triglyceride of docosahexaenoic acid (DHA) and a triglyceride of eicosapentaenoic acid (EPA) is used as an active ingredient for renal function maintenance and protection agents.

## Claims

### Claim 1

A renal function maintenance and protection agent comprising a triglyceride of docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) or a mixture of a triglyceride of docosahexaenoic acid (DHA) and a triglyceride of eicosapentaenoic acid (EPA) as an active ingredient for maintenance and protection of renal function.

### Claim 2 (depends on 1)

The renal function maintenance and protective agent according to claim 1, for oral administration to an administration target with the possibility of renal function deterioration due to hypertension.

### Claim 3 (depends on 1)

The renal function maintenance and protective agent according to claim 1, the triglyceride of DHA is a tridocosahexaenoyl glyceride (Tri-DHA-TG).

### Claim 4 (depends on 1)

The renal function maintenance and protective agent according to claim 1, comprising an oil and fat concentrate concentrated with the triglyceride of DHA, or the triglyceride of EPA or the triglyceride of DHA and the triglyceride of EPA.

### Claim 5 (depends on 4)

The renal function maintenance and protective agent according to claim 4, wherein the concentration of DHA in the oil and fat concentrate is 20% by mass or more.

### Claim 6 (depends on 1)

The renal function maintenance and protection agent according to claim 1, for administration to an applicable target at a dose of 1,000 mg/kg or more per day of DHA.

### Claim 7 (depends on 1)

The renal function maintenance and protective agent of claim 1, wherein the renal function maintenance and protection includes effects due to fibrosis inhibition, inflammation inhibition, spheroid podocyte injury inhibition and proximal tubule injury inhibition.

### Claim 8 (depends on 1)

The renal function maintenance and protection agent according to claim 1, which is for pharmaceutical use.

### Claim 9 (depends on 1)

The renal function maintenance and protection agent according to claim 1, which is a food composition.

### Claim 10 (depends on 1)

A method for evaluating an effect of administration of the renal function maintenance and protection agent according to claim 1, to an administration target, characterized by using at least one of the following indices A and B:
index A:
A concentration of N-acylated glycine metabolites (in creatinine equivalents) and/or niacinamide metabolites creatinine equivalents) in urine collected from the administration target,
Index B:
A concentration of at least one selected from 2-aminopimeric acid, 2-hydroxybutyric acid, citric acid, glycolic acid, phenylacetic acid and niacinamide in serum collected from the administration target.

### Claim 11 (depends on 10)

The method for evaluating according to claim 10, wherein the N-acylated glycine metabolite is N-phenylacetylglycine and/or N-isovaleroylglycine.

### Claim 12 (depends on 10)

The method for evaluating according to claim 10, wherein the niacinamide metabolite is at least one selected from 1-methylnicotinamide, nicotinamide N-oxide and nicotiurate.

### Claim 13 (depends on 11)

The method for evaluating according to claim 11, wherein a good prognosis can be predicted in advance at a stage where there is an increase in urinary concentration of (i) N-phenylacetylglycine and/or N-isovaleroylglycine relative to pre-administration or non-administration and/or (ii) at least one selected from 1-methylnicotinamide, nicotinamide N-oxide, and nicotiurate, due to the administration of a triglyceride of docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) or a mixture of a triglyceride of docosahexaenoic acid (DHA) and a triglyceride of eicosapentaenoic acid (EPA) to the administration target.

### Claim 14 (depends on 13)

The method for evaluating according to claim 13, wherein the increase in urinary concentration of (i) N-phenylacetylglycine and/or N-isovaleroylglycine and/or (ii) at least one selected from 1-methylnicotinamide, nicotinamide N-oxide, and nicotiurate, due to the administration is more than a 1.2 time increase over the pre-administration or non-administration.

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17 (depends on 10)

The method for evaluating according to claim 10, wherein a good prognosis can be predicted in advance at a stage where there is a variation of the index B with respect to pre-administration or non-administration due to the administration of a triglyceride of docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) or a mixture of a triglyceride of docosahexaenoic acid (DHA) and a triglyceride of eicosapentaenoic acid (EPA) to the administration target.

### Claim 18 (depends on 17)

The evaluation method according to claim 17, wherein the variation of the index B by the administration comprises at least one variation of any of the following:
(1) 2-Aminopimelic acid: not more than 0.8 times,
(2) 2-Hydroxybutyric acid: not more than 0.6 times,
(3) Citric acid: 0.85 times or less,
(4) Glucolic acid: not more than 0.80 times,
(5) Phenylacetic acid: not more than 0.2 times, and
(6) Niacinamide (niacinamide): 1.4 times or more.

### Claim 19

A method of a triglyceride of docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) itself or a mixture of a triglyceride of docosahexaenoic acid (DHA) and a triglyceride of eicosapentaenoic acid (EPA) as an active ingredient for renal function maintenance and protection in the production of renal function maintenance and protective agents.

### Claim 20 (depends on 16)

The method of claim 16, wherein the renal function maintenance and protection agent is the renal function maintenance and protection agent.

### Claim 21 (depends on 19)

The method of claim 19, wherein the effect of the renal function maintenance and protection agent is evaluated according to the method of evaluation.
